What is NewAmsterdam Pharma Company's revenue?

NewAmsterdam Pharma Company (NAMS) reported revenue of $3.04M in Q1 2026.

How has NewAmsterdam Pharma Company's revenue changed year-over-year?

NewAmsterdam Pharma Company's revenue increased by 2.1% year-over-year, from $2.98M to $3.04M.

What is the long-term trend for NewAmsterdam Pharma Company's revenue?

Over 3 years (2022 to 2025), NewAmsterdam Pharma Company's revenue has grown at a -39.7% compound annual growth rate (CAGR), from $102.69M to $22.5M.

NewAmsterdam Pharma Company NAMS Revenue

Revenue at other companies

HTF

Heartflow, Inc. Common StockHTFL

$52.59M+41.3%

Cal-Maine FoodsCALM

$666.95M-53.0%

DJT

Trump Media & Technology GroupDJT

$871.2K+6.1%

ADMA BiologicsADMA

$114.49M-0.3%

Minerals TechnologiesMTX

$546.9M+11.2%

PhotronicsPLAB

$209.94M-0.5%

Other financials

Income statement

See full

Revenue$3.0M+2.1%

Operating income-$58.4M+15.2%

Net income-$48.4M-22.6%

EPS (diluted)-$0.40-17.6%

Balance sheet

See full

Cash & equivalents$457.6M-38.9%

Total debt$23.0K-94.1%

Total equity$665.2M-14.4%

Total assets$732.6M-10.5%

Cash flow

See full

Operating cash flow-$30.6M+16.1%

CapEx$38.0K+138%

Free cash flow-$30.6M+16.0%

Valuation

See full

Market cap$3.67B+63.7%

Profitability

See full

Operating margin-953.6%-3,536pp

Net margin-942.8%-3,477pp

FCF margin-630.1%-6,324pp

Returns & leverage

See full

Return on equity-29.5%-1.8pp

Current ratio9.8×-10.2×

Where this comes from

Reported directly by NewAmsterdam Pharma Company in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: NewAmsterdam Pharma Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about NewAmsterdam Pharma Company's revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is NewAmsterdam Pharma Company's revenue?: NewAmsterdam Pharma Company (NAMS) reported revenue of $3.04M in Q1 2026.
How has NewAmsterdam Pharma Company's revenue changed year-over-year?: NewAmsterdam Pharma Company's revenue increased by 2.1% year-over-year, from $2.98M to $3.04M.
What is the long-term trend for NewAmsterdam Pharma Company's revenue?: Over 3 years (2022 to 2025), NewAmsterdam Pharma Company's revenue has grown at a -39.7% compound annual growth rate (CAGR), from $102.69M to $22.5M.